{"id":"y-6","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1476996","moleculeType":"Small molecule","molecularWeight":"366.42"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, Y-6 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"Y-6 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:10.188Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06635161","phase":"NA","title":"Trancranial Pulse Stimulation on Anterior Insula Cortex and Dorsal Anterior Cingulate Cortex","status":"RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2024-08-05","conditions":"Healthy Adults","enrollment":66},{"nctId":"NCT07040085","phase":"PHASE3","title":"Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-08-05","conditions":"Stroke","enrollment":892},{"nctId":"NCT06138834","phase":"PHASE2","title":"EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2023-11","conditions":"Acute Ischemic Stroke, Large Vessel Occlusion, Reperfusion","enrollment":300},{"nctId":"NCT05836766","phase":"PHASE2","title":"Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2023-06-05","conditions":"Acute Ischemic Stroke, Reperfusion, Large Vessel Occlusion","enrollment":120},{"nctId":"NCT04125030","phase":"","title":"Convergent and Concurrent Validity Between Clinical Recovery and Personal-civic Recovery in Mental Health","status":"SUSPENDED","sponsor":"Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal","startDate":"2019-08-05","conditions":"Psychotic Disorders, Mood Disorders","enrollment":200},{"nctId":"NCT01526525","phase":"PHASE4","title":"Perioperative Electroacupuncture on Postoperative Analgesia in Prostatectomy","status":"COMPLETED","sponsor":"G.Gennimatas General Hospital","startDate":"2009-07","conditions":"Pain, Postoperative","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Y-6","genericName":"Y-6","companyName":"Beijing Tiantan Hospital","companyId":"beijing-tiantan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Y-6 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}